Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) shares were down 4% during trading on Thursday after Scotiabank lowered their price target on the stock from $105.00 to $80.00. Scotiabank currently has a sector perform rating on the stock. Sarepta Therapeutics traded as low as $78.68 and last traded at $76.78. Approximately 123,747 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 1,192,278 shares. The stock had previously closed at $79.97.
Several other equities research analysts have also recently issued reports on SRPT. Cantor Fitzgerald reiterated an "overweight" rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft lowered their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Royal Bank of Canada reduced their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating for the company in a research note on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Finally, StockNews.com cut shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $167.41.
Check Out Our Latest Stock Analysis on SRPT
Insider Transactions at Sarepta Therapeutics
In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares of the company's stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 7.70% of the company's stock.
Institutional Investors Weigh In On Sarepta Therapeutics
A number of institutional investors have recently modified their holdings of the company. Louisiana State Employees Retirement System grew its position in Sarepta Therapeutics by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock valued at $3,222,000 after acquiring an additional 100 shares in the last quarter. EP Wealth Advisors LLC increased its stake in Sarepta Therapeutics by 2.2% during the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock worth $606,000 after buying an additional 105 shares during the period. Manchester Capital Management LLC lifted its holdings in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after buying an additional 110 shares in the last quarter. UMB Bank n.a. boosted its position in Sarepta Therapeutics by 36.0% in the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock valued at $63,000 after buying an additional 138 shares during the period. Finally, CIBC Asset Management Inc grew its stake in shares of Sarepta Therapeutics by 5.1% in the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after acquiring an additional 139 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.
Sarepta Therapeutics Stock Up 3.0 %
The firm has a market cap of $7.41 billion, a PE ratio of 61.06 and a beta of 0.79. The business has a 50-day moving average price of $106.35 and a two-hundred day moving average price of $117.47. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.
About Sarepta Therapeutics
(
Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
See Also
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
